Latest filing published 08 Oct 2026 for Alaunos Therapeutics, Inc., €14k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -89.7%Entry US$102.00 · Close at T+365 US$10.50
- +32.3%Entry US$330.00 · Close at T+365 US$436.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Robert W. Postma: trading record in brief
All filings by Robert W. Postma on record concern Alaunos Therapeutics, Inc., in the capacity of senior executive. We count 14 filings; the first trade dates from 4 March 2021 and the latest from 6 October 2026.
No open-market sale appears; the market trades are 3 purchases worth €580k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 11 share grants.
Half of the purchases are above €79k and half below. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -44.5%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 8 October 2026, the filings show a share grant worth €14k in Alaunos Therapeutics, Inc. The most recent open-market purchase was published on 1 December 2022, 1,438 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Robert W. Postma
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 21,829 shares@ US$0.74440.70% mcap2.4% of flowCommon StockSEC:0001193125-26-417969:0
- 8,463 shares@ US$1.920.58% mcap2.4% of flowCommon StockSEC:0001193125-26-318103:0
- 6,274 shares@ US$2.590.31% mcap2.4% of flowCommon StockSEC:0001193125-26-201489:0
- 5,622 shares@ US$2.892.4% of flowCommon StockSEC:0001193125-26-014116:0
- 5,142 shares@ US$3.162.4% of flowCommon StockSEC:0001193125-25-301026:0
- 4,050 shares0Common StockSEC:0000950170-25-094387:0
- 20,804 shares@ US$2.929.2% of flowCommon StockSEC:0000950170-25-054436:0
- 750,000 shares@ US$0.6581.1% of flowCommon StockSEC:0000899243-22-037275:0Canonical exit: 27 Feb 2023 (T+90)
- 40,000 shares0Common StockSEC:0000899243-22-023987:0
- 40,000 shares0Common StockSEC:0000899243-22-024005:0
- 54,492 shares@ US$1.7311.3% of flowCommon StockSEC:0001209191-21-054825:1Canonical exit: 1 Dec 2021 (T+90)
- 20,508 shares@ US$1.73100.0% of flowCommon StockSEC:0001209191-21-054825:0Canonical exit: 1 Dec 2021 (T+90)
- 2,500 shares0Common StockSEC:0001209191-21-030742:0
13 of 13 declarations